Dr Sara Hanning


Sara completed her PhD in pharmacy at the University of Otago in 2013 before taking a position as a research associate in paediatric pharmaceutics at UCL School of Pharmacy, UK. Sara returned to NZ in January 2017 and joined the University of Auckland as a Lecturer in Clinical Pharmacy Practice. Her research interests remain at the interface between pharmaceutics and clinical practice, with a focus on the development of safe and effective dosage forms for children.

Research | Current

Research interests

  • Paediatric formulation development
  • Novel drug delivery systems
  • Extemporaneous compounding
  • Acceptability of "child-friendly" dosage forms
  • Availability and accessibility of paediatric medicines


Pharmacy 213

  • Course Director
  • Module leader, Infectious Diseases

Pharmacy 412

  • Module leader, Paediatrics

Selected publications and creative works (Research Outputs)

As of 29 October 2020 there will be no automatic updating of 'selected publications and creative works' from Research Outputs. Please continue to keep your Research Outputs profile up to date.
  • Hanning, S. M., Medlicott, N. J., & Oliphant, E. A. (2019). Clinical Pharmacy Considerations in Special Population: Pediatrics. In Z. Babar (Ed.) Encyclopedia of Pharmacy Practice and Clinical Pharmacy (pp. 815-830). Academic Press. 10.1016/B978-0-12-812735-3.00574-4
    URL: http://hdl.handle.net/2292/47798
    Other University of Auckland co-authors: Elizabeth Oliphant
  • Hanning, S. M., Orlu Gul, M., Toni, I., Neubert, A., Tuleu, C., & CloSed Consortium (2017). A mini-review of non-parenteral clonidine preparations for paediatric sedation. Journal of Pharmacy and Pharmacology, 69 (4), 398-405. 10.1111/jphp.12662
  • Hanning, S. M., Orlu Gul, M., Winslade, J., Baarslag, M. A., Neubert, A., Tuleu, C., & CloSed Consortium (2016). Quality and clinical supply considerations of Paediatric Investigation Plans for IV preparations - A case study with the FP7 CloSed project. International Journal of Pharmaceutics, 511 (2), 1158-1162. 10.1016/j.ijpharm.2016.04.051

Contact details

Primary office location

M&HS BUILDING 505 - Bldg 505
Level 3, Room 366
New Zealand